الفهرس 
Evaluation of the potential anticancer effect of a novel chalcone derivative in ehrlich solid carcinoma-bearing mice
Table of ContentsOnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
Globally, the number of new cancer cases is rising at an alarming pace. Modern cancer therapy is thought to have the least adverse effects, driving the development of safer therapeutic options. Chalcones are a group of flavonoids and isoflavonoid precursors, and their synthetic analogs show a promising potential for developing anticancer drugs. Thus, the current study was conducted to evaluate the anticancer activity of a synthetic isoquinoline chalcone (CHE) against the triple negative-breast cancer cell line MDA-MB-231 in vitro and Ehrlich solid carcinoma bearing mice in vivo in comparison with the traditional chemotherapeutic drug doxorubicin. To study the anticancer activity of CHE in vitro, the cell viability of MDA-MB-231 cells was evaluated by crystal violet assay using four different concentrations of CHE (25, 50, 100, 250 og/ml). In vivo anticancer activity of CHE was evaluated by three different doses (107, 214, and 321 mg/kg) based on the maximum tolerated dose (428 mg/kg). CHE treatment groups were intraperitoneally injected twice per week for two weeks and compared with doxorubicin (4 mg/kg). Subsequently, oxidative stress was determined by total antioxidant capacity, DNA damage was assessed by DNA fragmentation and comet assays, apoptosis-related genes (p53, Bax, Caspase3, and Bcl-2) were evaluated in tumor tissues of untreated and CHE-treated mice groups. Furthermore, protein expression of the proliferative marker Ki67 and bax were immunohistochemically evaluated. In vitro CHE treatment significantly reduced cell proliferation of MDA-MB-231 cells